Viridian Therapeutics, Inc. · NASDAQ:VRDN
Viridian Therapeutics — Corporate Update (June 2026)
28 slides from Viridian Therapeutics's corporate update, Jun 29, 2026
Slide 1: Lumvoa (veligrotug-vvze) FDA Approval
LumvoaTM (veligrotug-vvze) FDA Approval June 29, 2026
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements This presentation and the related teleconference contain forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,”
Slide 3: Agenda
Agenda Steve Mahoney CEO Opening Remarks President & Chief Executive Officer Lumvoa Labeling Radhika Tripuraneni, MD and Key Clinical Data Chief Medical Officer Tony Casciano Commercial Strategy and Launch Chief Commercial Officer Steve Mahoney Closing Remarks President & Chief Executive Officer Ste
Slide 4: CEO Opening Remarks
CEO Opening Remarks Steve Mahoney 4
Slide 5: Lumvoa now FDA approved
LumvoaTM now FDA approved First approved treatment for TED with both active and chronic TED data in label Approved under Priority Review 5 FDA = U.S. Food & Drug Administration, TED = thyroid eye disease.
Slide 6: TED is an autoimmune condition characterized by inflammation, growth, and damage around the eyes
TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eyes Heterogeneous autoimmune disease1,2 Signs and symptoms include proptosis (eye bulging), redness, swelling, diplopia (double vision), and lid retraction1,2 Severe cases can cause sig
Slide 7: Lumvoa showed rapid, consistent, and durable reductions of key symptoms in active and chronic TED
Lumvoa treatment showed rapid, consistent, and durable reductions of key symptoms in both active and chronic TED Both THRIVE and THRIVE-2 met their primary and all secondary endpoints1,2 • Consistently demonstrated statistically significant improvements across all of the key signs and symptoms of TE
Slide 8: Lumvoa Labeling and Key Clinical Data
Lumvoa Labeling and Key Clinical Data Radhika Tripuraneni, MD 8
Slide 9: Lumvoa's broad label supported by positive pivotal phase 3 trials
Lumvoa’s broad label supported by positive pivotal phase 3 trials in active and chronic TED Highlights of Prescribing Information1 9 1. Lumvoa (veligrotug-vvze) prescribing information. Viridian Therapeutics, Inc. 2026. TED = thyroid eye disease
Slide 10: Lumvoa was studied in the largest and broadest population of TED patients
Lumvoa was studied in the largest and broadest population of TED patients in studies completed to date Study Designs4,5 Active TED (THRIVE) Chronic TED (THRIVE-2) THRIVE (N=113) THRIVE-2 (N=188) Recent-onset active TED patients1,2 Chronic TED patients1,3 Moderate-to-severe active TED Moderate-to-sev
Slide 11: Active TED (THRIVE): statistically significant results across all endpoints
Active TED (THRIVE): statistically significant results across all endpoints Study Designs Active Active TED (THRIVE) TED (THRIVE) Chronic TED (THRIVE-2) Lumvoa Placebo P value Responder rate, week 15 70% 5% P < 0.0001 Proptosis1,2 Mean reduction (CFB) 2.9 mm 0.5 mm P < 0.0001 Responder rate, week 15
Slide 12: Rapid, robust, durable reductions in proptosis for active TED
Lumvoa treatment led to rapid, robust, and durable reductions in proptosis for patients with active TED Study Designs Active Active TED (THRIVE) TED (THRIVE) Chronic TED (THRIVE-2) 70% of patients had proptosis Proptosis reduction of response at week 151* 2.90 mm at week 151† Weeks 70% Lumvoa N=75 P
Slide 13: Diplopia improvement in active TED; nearly half had complete resolution
Lumvoa resulted in diplopia improvement for the majority of active TED patients; nearly half had complete resolution Study Designs Active Active TED (THRIVE) TED (THRIVE) Chronic TED (THRIVE-2) 59% of patients had improvement in 49% had complete resolution of diplopia diplopia at week 151 4x more th
Slide 14: Chronic TED (THRIVE-2): statistically significant results across all endpoints
Chronic TED (THRIVE-2): statistically significant results across all endpoints Study Designs Active TED (THRIVE) Chronic TED(THRIVE-2) Chronic TED (THRIVE-2) Lumvoa Placebo P value Responder rate, week 15 57% 8% P < 0.0001 Proptosis1,2 Mean reduction (CFB) 2.4 mm 0.5 mm P < 0.0001 Responder rate, we
Slide 15: Rapid, robust, durable reductions in proptosis for chronic TED
Lumvoa treatment led to rapid, robust, and durable reductions in proptosis for patients with chronic TED Study Designs Active TED (THRIVE) Chronic TED(THRIVE-2) Chronic TED (THRIVE-2) 57% of patients had proptosis Proptosis reduction of response at week 151* 2.35 mm at week 151† Week Lumvoa Placebo
Slide 16: Diplopia improvement in chronic TED; nearly a third had complete resolution
Lumvoa resulted in diplopia improvement for the majority of chronic TED patients; nearly a third had complete resolution Study Designs Active TED (THRIVE) Chronic TED(THRIVE-2) Chronic TED (THRIVE-2) 56% of patients had improvement in 32% had complete resolution of diplopia diplopia at week 151 2x m
Slide 17: Lumvoa safety and tolerability profile in active and chronic TED
Lumvoa safety and tolerability profile in active and chronic TED Adverse reactions occurring in 5% or more of patients with active or chronic TED1 Lumvoa Placebo N=200 N=101 Adverse Reactions N (%) N (%) Muscle spasms 79 (40%) 7 (7%) Headache 34 (17%) 14 (14%) Hearing impairment* 29 (15%) 6 (6%) Hyp
Slide 18: Commercial Strategy and Launch
Commercial Strategy and Launch Tony Casciano 18
Slide 19: Lumvoa is launching into a large and attractive TED market
Lumvoa is launching into a large and attractive TED market Large and Focused and Favorable Established Market Experienced Footprint Market Dynamics $2B ~2,000 New Start Market TED market with core prescribers enabling rapid uptake potential to grow experienced with potential anti-IGF-1R infusions Si
Slide 20: Lumvoa Launch Priorities
Lumvoa Launch Priorities DRIVE Awareness DIFFERENTIATE Lumvoa DELIVER Access Rapid engagement of core Simple enrollment, strong Broad payer coverage and Lumvoa customers: anti- clinical profile, and short world-class patient IGF-1R prescribers and treatment duration services infusion centers DEMONST
Slide 21: DRIVE AWARENESS: Experienced field team targeting key U.S. stakeholders
DRIVE AWARENESS: Experienced and geographically-aligned field team targeting key U.S. stakeholders ~2000 Payers and infusion core anti-IGF-1R centers prescribers Field Sales Market (<100) Access KOLs and Physician staff physicians and patients Medical Patient Avg experience: Affairs Services 20+ yea
Slide 22: DIFFERENTIATE LUMVOA: potential to redefine the treatment paradigm for TED
DIFFERENTIATE LUMVOA: Lumvoa has the potential to redefine the treatment paradigm for TED patients Strong label allows us to focus on key points of differentiation Demonstrated strong clinical data with robust improvements in proptosis and diplopia in both active and chronic TED Rapid symptom relief
Slide 23: DELIVER ACCESS: Market access readiness enables immediate prescribing
DELIVER ACCESS: Market access readiness enables physicians to prescribe Lumvoa immediately Pre-Launch Payer Engagements Facilitate Anticipate Rapid Access at Launch Rapid Coverage and Access Majority of anti-IGF-1R • Pre-approval Information patients are commercially Exchange (PIE) meetings with c
Slide 24: DELIVER ACCESS: ViridianCares supports patients and physician offices
DELIVER ACCESS: ViridianCares designed to support patients and physician offices throughout their journey • Personalized, one-on-one support to help your patients throughout their treatment journey • Assistance with benefits verification, prior authorization requirements, reimbursement, and required
Slide 25: Closing Remarks
Closing Remarks Steve Mahoney 25
Slide 26: Multiple differentiated treatment solutions for TED patients in one portfolio
Viridian has the potential to provide multiple differentiated treatment solutions for TED patients in one portfolio Elegrobart Elegrobart Q4W Q8W Well-positioned to be a Potential to be the first subcutaneous meaningful treatment autoinjector in TED, providing a simple, option for TED patients infre
Slide 27: Viridian aspires to lead in TED and autoimmune diseases
Viridian aspires to lead in TED and autoimmune diseases Autoimmune Thyroid FcRn New Pipeline INDs and POCs* Expansion* TSHR, FcRn POCs* TED Ele Launch** Lumvoa Launch Expand 2026 • Leadership beyond TED Extend • Continued pipeline through discovery and development • Advance TSHR (potential in TED an
Slide 28: Q&A
Q&A N lA VIRID ae